Abstract: The disclosure relates to a detector arrangement for detecting a position of an object with regard to a first direction, wherein the object includes a front edge and a rear edge separated from each other in the first direction and wherein the object is movable relative to the detector arrangement in the first direction. The detector arrangement includes a first detector configured to detect electromagnetic radiation, the first detector including a first detection area sensitive to the electromagnetic radiation, wherein the detection area is confined by a first detection front edge and by a first detection rear edge, wherein the first detection front edge is separated from the first detection rear edge in the first direction. At least one of the first detection front edge and the first detection rear edge extends non-parallel to at least one of the front edge and the rear edge of the object.

Abstract: A drug delivery device, comprising housing comprising one or more bridging contacts; a movable dial located at least partially within the housing and arranged to move relative to the one or more bridging contacts, the movable dial comprising a series of conductive strips on an exterior surface of the movable dial, wherein the one or more bridging contacts selectively connect and disconnect conductive strips of the series of conductive strips as the movable dial moves to provide alternating electrical signals; at least one electronic component configured to: detect the alternating electrical signals; determine whether the alternating electrical signals are indicative of contact between conductive strips of the series of conductive strips and the one or more bridging contacts; and based on the alternating electrical signals, determine a medicament dosage programmed into the drug delivery device.

Abstract: Systems and methods for generating potential medicinal molecules using memory networks are descried. A method for generating analogs of a molecule includes: receiving one or more initial molecular structures; generating one or more of token string representations for each of the one or more initial molecular structures, each token string representation corresponding to an analog of a corresponding initial molecular structure. Generating the token string representations of analogs includes, for each further token string representation: sequentially processing a token string representation of a substructure of the corresponding initial molecular structure using a memory network; and subsequent to processing the token string representation of a substructure, sampling one or more additional tokens using the memory network. The token string representations each comprise a plurality of tokens representing predefined structures of a molecule.

Abstract: The present disclosure provides compounds which are peptides comprising the amino acid sequence of the formula (I) disclosed herein or pharmaceutically acceptable salts thereof. The compounds act as agonists of the corticotropin-releasing factor receptor 2 (CRF2) and are useful in therapy, especially in the treatment or prevention of cardiovascular diseases, obesity and diabetes.

Abstract: A dispenser for attachment to a medicament container is configured to convey a dose of medicament. The dispenser includes an outer part having a dose dispensing chamber, a circumferential wall and a dose dispensing outlet in the circumferential wall. An inner part is rotatably disposed within the outer part and has a dosing aperture, a circumferential wall, and a dose dispensing outlet in the circumferential wall. The outer part is rotatable relative to the inner part between a dosing position, in which the dosing aperture communicates with the dose dispensing chamber to allow a dose to pass through the dosing aperture and into the dose dispensing chamber, and a dispensing position, in which the dose dispensing chamber, the outlet in the circumferential wall, and the outlet in the circumferential wall align to define a dose dispensing path out of the dispenser for delivery of the dose to a user.

Abstract: A computer-implemented method of generating a molecule includes sequentially processing, by a memory network, each token in a token string representation of a molecular scaffold to generate a molecule, wherein the token string representation comprises a plurality of tokens representing predefined structures of the molecular scaffold and one or more tokens representing open positions of the molecular scaffold, and wherein the memory network encodes a sequential probability distribution on the tokens using an internal state of the memory network. The method further includes outputting, from the memory network, a token string representation of the generated molecule. Sequentially processing each token in the token string representation of the molecular scaffold includes determining whether or not a current token being processed is a token representing an open position of the molecule.

Abstract: A dose counting system of an injection device or of a module configured to be used with or applied to an injection device is described. The dose counting system includes a sensor arrangement including a first sensor configured to output a first signal and a second sensor configured to output a second signal; and a processor configured to: detect a peak in the first signal when the first signal has increased by at least a predefined up threshold and the first signal exceeds the value of the second signal by more than a predetermined crossover threshold; determine that a unit of medicament has been administered when the first signal drops from the peak by more than a predefined down threshold and the preceding peak occurred in the second signal; and determine a medicament dosage administered by the injection device by counting the administered units of medicament.

Abstract: The disclosure relates to a dosage measurement system for a medicament delivery device. The medicament delivery device includes a medicament reservoir and a dispensing mechanism. The dispensing mechanism includes a dispensing member that is moveable axially to dispense medicament from the medicament reservoir. The dosage measurement system includes a sensor unit and a processor. The sensor unit is configured to measure the axial displacement of the dispensing member. The processor is configured to determine a dosage dispensed from the medicament reservoir based on the measured axial displacement of the dispensing member.

Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).

Abstract: The present invention relates to amino acid sequences that can bind to serum albumin. In particular, the present invention relates to immunoglobulin single variable domains, and in particular heavy-chain immunoglobulin single variable domains, that can bind to serum albumin. The invention also relates to proteins, polypeptides and other constructs, compounds, molecules or chemical entities that comprise at least one of the immunoglobulin single variable domains binding to serum albumin that are described herein.

Abstract: The present invention relates to a compound of the formula (I) or a pharmaceutically acceptable salt thereof: wherein: R1 represents a hydrogen atom, a halogen atom, or a (C1 C4)hydroxyalkyl group, R2 represents a (C1-C6)alkyl group, and R3 represents a hydrogen atom, a (C1-C4)alkyl group or a halogen atom, and Ar represents a divalent aromatic ring or a (C5-C11) heteroarylene group. It further relates to the therapeutic uses thereof, in particular as anticancer agents.

Abstract: The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), Crohn's disease or ulcerative colitis.

Abstract: A packaging assembly comprises a case configured to contain at least one injection device for delivering a medicament; a cooling unit configured to lower an internal temperature of the case; a processing arrangement; a device sensor configured to detect at least one injection device contained within the case, and to receive device storage information from the at least one detected injection device; and a data storage device. The processing arrangement is configured to record an injection history on the data storage device. The processor arrangement is configured to control the cooling unit to set an internal temperature of the case according to the received device storage information.

Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.

Abstract: The present disclosure concerns antibody-conjugates comprising an anti-CEACAM5-antibody for use for treating cancer in combination with an anti-VEGFR-2 antibody. The disclosure further relates to pharmaceutical compositions and kit-of-parts comprising an anti-CEACAM5-antibody in combination with anti-VEGFR-2 antibody for use for treating cancer.

Abstract: The present technology aims at providing a novel type of drug for treating a subject suffering from an inflammatory disease. Specifically, the present technology provides polypeptides comprising at least four immunoglobulin single variable domains (ISVDs), characterized in that at least two ISVDs bind to IL-13 and at least two ISVDs binds to TSLP. The present technology also provides nucleic acids, vectors and compositions.

Abstract: The invention provides antibodies that specifically bind to Plasminogen Activator inhibitor type-1 (PAI-1), The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-PAI-1 antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies to modulate PAI-1 activity or detect PAI-1, either in vitro or in vivo, are also provided. The disclosure further provides methods of making antibodies that specifically bind to PAI-1 in the active conformational state.

Abstract: The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine.